If you have been reading about lyophilised powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised and often hygroscopic |
| Solubility class | Freely soluble in water | Poor solubility in non-polar solvents |
| Typical storage temperature | -20 degrees Celsius or colder | Sealed, desiccated, protected from light |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Establishes purity and confirms mass |
| Common salt form | Trifluoroacetate or acetate | Counterion reported alongside purity values |
Identity confirmation uses mass spectrometry, usually electrospray ionisation in positive mode or matrix-assisted laser desorption. The protonated free peptide produces a signal near three hundred and ninety-one daltons, while salt adducts shift that value slightly. Tandem mass spectrometry or amino acid analysis supplies sequence-level confirmation, which a single mass measurement cannot. Peptides containing aspartate can cyclise into succinimide intermediates that hydrolyse to isoaspartate isomers of identical mass. Because those isomers are difficult to separate chromatographically, identity and purity results carry more weight when interpreted together.
Storage practice centres on limiting moisture, oxygen, and repeated temperature cycling. Freeze-dried powder is generally held desiccated at minus twenty degrees Celsius or colder and protected from light. Reconstituted solutions are markedly less stable, and the aspartate-glycine junction is prone to succinimide formation at neutral to mildly alkaline pH. Portioning material into single-use aliquots reduces degradation compared with repeated freeze-thaw cycles. Stability data specific to this tetrapeptide remain scarce, so most handling guidance is extrapolated from general peptide chemistry rather than measured directly.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
== History == The earliest conception of PeptideAtlas began at the Institute for Systems Biology in the research lab of Ruedi Aebersold by Eric Deutsch and Sharon Chen at the Annotated Peptide Database (APD). The concept was further expanded with additional efforts from Parag Mallick and Frank Desiere. The first instance for an ensemble of human experiments was published in 2004 as the Human PeptideAtlas. The concept was further expanded to many other species over the years with major effort by Nichole King, Zhi Sun, Terry Farrah, and Dave Campbell.
Acanthosis nigricans associated with malignancy (acanthosis nigricans type I) Acanthosis nigricans associated with obesity, insulin-resistant states, and endocrinopathy (acanthosis nigricans type III) Acral acanthosis nigricans (acral acanthotic anomaly) Acral dry gangrene Acromegaly Addison's disease Adrenal adenoma Adrenal carcinoma Adrenal hyperplasia Alopecia–nail dystrophy–ophthalmic complications–thyroid dysfunction–hypohidrosis–ephelides and enteropathy–respiratory tract infections syndrome (ANOTHER syndrome) Arrhenoblastoma Cretinism Cushing's syndrome Excess ovarian androgen release syndrome (ovarian SAHA syndrome) Familial acanthosis nigricans (acanthosis nigricans type II) Growth hormone deficiency Hyperandrogenism–insulin resistance–acanthosis nigricans syndrome (HAIR-AN syndrome) Hyperparathyroidism Hyperprolactinemic SAHA syndrome Hyperthyroidism Hypoparathyroidism Hypothyroidism Leydig cell tumor Multiple endocrine neoplasia type 1 (Wermer syndrome) Multiple endocrine neoplasia type 2 (multiple endocrine neoplasia type 2A, pheochromocytoma and amyloid-producing medullary thyroid carcinoma, PTC syndrome, Sipple syndrome) Multiple endocrine neoplasia type 3 (mucosal neuromata with endocrine tumors, multiple endocrine neoplasia type 2B, multiple mucosal neuroma syndrome, Wagenmann–Froboese syndrome) Myxedema Panhypopituitarism Persistent adrenarche syndrome (adrenal SAHA syndrome) Polycystic ovarian syndrome Seborrhoea–acne–hirsutism–alopecia (SAHA syndrome) Thyroid acropachy
Diets high in saturated fat are linked to heart diseases, and males with heart diseases are more likely to experience ED. By contrast, plant-based diets show a lower risk for ED. Prescription drugs (e.g., SSRIs, beta blockers, antihistamines, alpha-2 adrenergic receptor agonists, thiazides, hormone modulators, and 5α-reductase inhibitors) Neurogenic disorders (e.g., diabetic neuropathy, temporal lobe epilepsy, multiple sclerosis, Parkinson's disease, multiple system atrophy) Cavernosal disorders (e.g., Peyronie's disease) Hyperprolactinemia (e.g., due to a prolactinoma) Psychological causes: performance anxiety, stress, and mental disorders Surgery (e.g., radical prostatectomy) Ageing: after age 40 years, ageing itself is a risk factor for ED, although numerous other pathologies that may occur with ageing, such as testosterone deficiency, cardiovascular diseases, or diabetes, among others, appear to have interacting effects Kidney disease: ED and chronic kidney disease have pathological mechanisms in common, including vascular and hormonal dysfunction, and may share other comorbidities, such as hypertension and diabetes mellitus that can contribute to ED Lifestyle habits, particularly smoking, which is a key risk factor for ED as it promotes arterial narrowing. Due to its propensity for causing detumescence and erectile dysfunction, some studies have described tobacco as an anaphrodisiacal substance. COVID-19: preliminary research indicates that COVID-19 viral infection may affect sexual and reproductive health.
Sources: en.wikipedia.org
The president had only joined the cry of "Down with the Republicans!" in Montalembert in the hope of effecting a revision of the constitution without having recourse to a coup d'état. His concessions only increased the boldness of the monarchists, who had only accepted Louis-Napoléon as president in opposition to the Republic and as a step in the direction of the monarchy. A conflict was now inevitable between his personal policy and the majority of the Chamber, who were divided into legitimists and Orléanists in spite of the death of Louis-Philippe in August 1850. Louis-Napoléon exploited their projects for a restoration of the monarchy, which he knew to be unpopular in the country, and which gave him the opportunity of furthering his own personal ambitions. From 8 August to 12 November 1850 he went about France stating the case for a revision of the constitution in speeches which he varied according to each place; he held reviews, at which cries of "Vive Napoléon!" showed that the army was with him; he superseded General Changarnier, on whose arms the parliament relied for the projected monarchical coup d'état; he replaced his Orléanist ministry with obscure men devoted to his own cause, such as Morny, Fleury and Persigny, and gathered round him officers of the African army, broken men like General Saint-Arnaud; in fact he practically declared open war.
=== June === 1 June House prices in the UK are reported to have fallen by 3.4% in the year to May, the biggest decline since July 2009. The average property price is now estimated at £260,736. A ban on e-scooters carried on Southeastern, Southern, Thameslink and Gatwick Express trains comes into force, due to concerns over fire risk. 2 June – A visibly emotional Phillip Schofield gives an interview with the BBC's Amol Rajan, in which he apologises and says his "career is over" following the affair with a young male colleague. 3 June Train strikes staged by the ASLEF union cause disruption to the 2023 FA Cup final and a Beyoncé Knowles concert. In the FA Cup Final, the first in the 152-year history of the competition to feature a Manchester derby, Manchester City defeat rivals Manchester United 2–1 to win their seventh FA Cup trophy. A man is arrested at the FA Cup final after being pictured wearing a Manchester United shirt with the number 97 and the slogan "not enough", believed to be a reference to the Hillsborough disaster. The 33-year-old male is subsequently charged with displaying threatening or abusive writing likely to cause harassment, alarm or distress. A protestor is detained by police after attempting to disrupt the 2023 Epsom Derby by trespassing on the track. 6 June Record high numbers of gonorrhoea and syphilis infections are reported, following a dip during previous years.
==== Immunological biosensor ==== Gold nanoparticles have been coated with peptides and glycans for use in immunological detection methods. The possibility to use glyconanoparticles in ELISA was unexpected, but the method seems to have a high sensitivity and thus offers potential for development of specific assays for diagnostic identification of antibodies in patient sera.
=== Plant-based medications === There has been a number of alternative therapies experimented in ayurvedic medicine with plant-based products, although none have provided good evidence of efficacy. A recent study showed that the stromal processing peptidase (SPP), a synthetic enzyme found in plant chloroplasts, prevented the aggregation of proteins associated with Huntington's disease. However, repeat studies and clinical validation are needed to confirm its true therapeutic potential.
Sources: en.wikipedia.org
Sealed lyophilised powder is normally kept at minus twenty degrees Celsius or below, away from light and moisture. Vials are allowed to reach room temperature before opening to limit condensation. Repeated warming and cooling of the same vial is discouraged.
Reversed-phase HPLC establishes purity and separation from related peptides, and mass spectrometry confirms the molecular mass. Amino acid analysis can verify residue composition. No single method proves identity on its own, so the results are read together.
Yes. Residual trifluoroacetate or acetate from purification adds mass and can shift the value obtained by certain assays. Purity figures are therefore meaningful only when the counterion form is stated. Reporting both peptide content and salt form gives a clearer picture.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.